Pulmonary Neoplasms
18
2
3
10
Key Insights
Highlights
Success Rate
71% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 87/100
22.2%
4 terminated out of 18 trials
71.4%
-15.1% vs benchmark
0%
0 trials in Phase 3/4
20%
2 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (18)
Enhanced COPD Management in Suspected Lung Cancer Patients
Feasibility of Fluorescence Imaging With Bevacizumab-800CW During Bronchoscopy
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Precision Lung Cancer Survivorship Care Intervention
Identification of Prognostic Biomarkers for Progression of Invasive Squamous Cell Carcinoma
Remote Monitoring of Lung Cancer Patient-Reported Outcomes Using Moovcare®
MARK 1A Series: Percutaneous Microwave Ablation for Patients With Lung Tumor(s)
A Phase I Study of iPS Cell Generation From Patients With COPD
Isolating and Testing Circulating Tumor DNA and Soluble Immune Markers During the Course of Treatment for Lung Cancer
Study of Arsenic Trioxide in Small Cell Lung Cancer
A Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System
RejuvenAir Lobectomy for Safety and Histology
Study of Preoperative Docetaxel or Cisplatin (CDDP) + Docetaxel for C-stage IB-II Non-Small Cell Lung Cancer (NSCLC)
Diagnosis of Lung Lesions by Endobronchial Ultrasound With an Alternative Guide Sheath
Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide
Protocol for Radiofrequency Ablation of Pulmonary Neoplasms
Bronchial Ultrasonography Via a Fibrescope: Pilot Study in Tumoral Disease
A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.